News

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding.

Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both patients and clinicians. It provides access to real time data, simplifies workflows, and features a design intended to improve mobility and independence.

For Luminoah founder Neal Piper, this milestone reflects six years of innovation shaped by personal experience with enteral nutrition during his son’s cancer treatment.

“FDA clearance of Luminoah Flow marks a major milestone in our mission to transform enteral nutrition,” said Neal Piper, Founder and Chief Executive Officer of Luminoah. “Inspired by my family’s experience, we built Luminoah to address persistent challenges faced by patients and caregivers. Patients living with feeding tubes need solutions that integrate more naturally into daily life, and Luminoah Flow brings together modern technology and patient centered design to better support patients, caregivers, and clinicians.”

“One of the biggest gaps in enteral care today is limited visibility once patients leave the hospital,” said Dr. Gary Nace Jr., Pediatric Surgeon at Children’s Hospital of Philadelphia. “Clinicians often rely on reported information rather than objective data when managing nutrition outside the hospital. A system like Luminoah Flow may help provide greater visibility into what is being delivered at home and support more informed clinical decision making.”

“Enteral nutrition is a critical therapy for millions of patients, yet the technology supporting it has changed very little over time,” said Tegan Medico, MS, MPH, RDN, CNSC, Clinical Dietitian at UVA Health. “Much of the burden still falls on patients and caregivers to manage feeds and communicate what is happening at home. A system like Luminoah Flow may help bring greater simplicity and visibility to that process, allowing clinicians to better support patients between visits.”

Key Features of Luminoah Flow Include:

  • Compact, lightweight design that enhances mobility and discretion

  • Real time data tracking to support visibility into nutrition delivery

  • Modern touchscreen pump interface for both patients and caregivers

  • Eco-friendly USB-C charging capability for flexibility and convenience

“This clearance reflects the work our team has put into solving a deeply important problem,” said Garrett Marin, Chief Operating Officer at Luminoah. “We are excited to bring a solution to market that meets regulatory standards while improving day to day care for patients and providers.”

Luminoah plans to begin a phased commercial rollout of Luminoah Flow across the United States, working closely with healthcare providers, home health organizations, and patient communities.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business